READOUT · 04 / DOSAGE
BPC-157 TB-500 Dosage: What the Research Literature Records
There is no validated dose for the blend. The numbers below are animal-model figures and human single-agent reference points, reported as research context — not a regimen.
BPC-157 TB-500 Dosage in the Research Literature
BPC-157 TB-500 dosage has no validated figure at the blend level. No peer-reviewed combination dose-finding study exists, so every number associated with the pairing comes from single-compound animal work or from human studies of one constituent in isolation. Commercial research-product vials commonly pair the two at fixed combined masses — for example ~10 mg BPC-157 plus ~10 mg TB-500, or a 20 mg combined vial — but those label ratios have no controlled-trial basis [9].
The rodent figures, expressed per body weight and never translatable to a human regimen: BPC-157 was studied frequently at ~10 microg/kg and ~10 ng/kg, with gastric-ulcer cytoprotection at 400-800 ng/kg in rats [1]. The TB-500 / Thymosin Beta-4 side spans a wide range — 2-18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study (optimal modeled near 3.75 mg/kg, with 18 mg/kg giving no benefit), and 150 microg twice weekly intraperitoneally for six months in an mdx muscular-dystrophy study [4]. Human single-agent reference points exist only for full-length Thymosin Beta-4 — intravenous Thymosin Beta-4 tolerated to high single doses in a Phase 1 program — not for the heptapeptide and not for the blend [9]. These are doses studied in named species and contexts, not instructions.
What is the half-life of BPC-157 and TB-500?
Half-life is one of the most-asked dosing questions for the blend, and it is one the literature largely cannot answer.
What is the half-life of BPC-157 and TB-500?
No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. BPC-157 elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study; human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [9].
How do you reconstitute a BPC-157 / TB-500 blend?
Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated; a common practice is to reconstitute them separately or in a shared vial. Product identity, purity and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [9]. This describes research handling, not a human-use instruction.
BPC 157 TB 500 Oral vs Injected
BPC 157 TB 500 oral products are marketed, but the pharmacokinetic case for them is uneven. BPC-157 is studied as a "stable gastric" peptide and has been administered perorally in rodent models, which is the basis of the oral framing [9]. TB-500 is a different molecule with no validated oral pharmacokinetics, and blend oral products lack validated absorption data entirely. The underlying efficacy studies for both peptides most often used injected routes — intraperitoneal in rodents, with subcutaneous and intramuscular predominant in research-community handling of the blend [1][9]. Oral versus injected is therefore not a settled question for the pairing; it is two different molecules with two different absorption pictures and no combination pharmacokinetic study to reconcile them.
How often should you inject BPC-157 and TB-500?
There is no validated dose or schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg plus 10 mg) have no basis in controlled human trials [9]. The underlying rodent studies used per-body-weight dosing that does not translate to a human regimen [1]; framing stays research-only.
How do you cycle BPC-157 and TB-500?
Cycling protocols circulate widely in forums and rest on no controlled evidence, and one preclinical result actively cuts against the "more is better" logic that loading schedules assume.
How do you cycle BPC-157 and TB-500?
No validated cycling protocol exists; community "loading then maintenance" schedules have no controlled-trial basis. A rat embolic-stroke study even found Thymosin Beta-4 dosing non-monotonic — 18 mg/kg gave no benefit — undermining "more is better" loading rationales [4]. Any cycle described in forums is not validated dosing.